Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 256 for:    "methodist hospital" | Recruiting, Not yet recruiting, Available Studies | Houston

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03742245
Recruitment Status : Not yet recruiting
First Posted : November 15, 2018
Last Update Posted : March 5, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Jenny C. Chang, MD, The Methodist Hospital System

Brief Summary:
The purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Metastatic Breast Cancer Drug: Olaparib Drug: Vorinostat Phase 1

Detailed Description:

This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this causes damage to their DNA (genetic makeup). Cancer cells that cannot repair this damage will not survive and die. Unfortunately, cancer cells contain certain proteins whose job is to repair DNA damage. Poly (adenosine 5' diphosphoribose) polymerase (PARP) and histone deacetylase (HDAC) are two such proteins. Olaparib stops PARP from working, and vorinostat stops histone deacetylase from working. The use of olaparib and vorinostat together may better block the ability of cancer cells to repair their DNA damage. This may lead to even better killing of cancer cells.

The study will be done in two parts. In part one of the study, different dose levels of olaparib and vorinostat will be tested in several study participants. This part of the study will allow us to see the doses of olaparib and vorinostat that can be used safely together in participants with relapsed/refractory and/or metastatic breast cancer. Up to 4 different dose levels will be studied. In part two of the study, the dose level of olaparib and vorinostat found to be the safest in the first part of the study will be tested. This part of the study will allow us to see how well relapsed/refractory and/or metastatic breast cancer responds to treatment with olaparib and vorinostat. Participants who received the dose level of olaparib and vorinostat found to be the safest in the first part of the study will also take part in part two of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Estimated Study Start Date : April 1, 2019
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : September 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Olaparib and Vorinostat

Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.

Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression.

Drug: Olaparib
PARP inhibitor
Other Names:
  • AZD2281
  • KU-0059436
  • Lynparza

Drug: Vorinostat
HDAC inhibitor
Other Names:
  • Suberanilohydroxamic acid
  • Zolinza




Primary Outcome Measures :
  1. MTD [ Time Frame: 16 weeks ]
    Determine the MTD of the olaparib and vorinostat combination


Secondary Outcome Measures :
  1. Dose-limiting toxicities (DLTs) and other adverse events [ Time Frame: 16 weeks ]
    Determine the DLTs and other adverse events associated with the olaparib and vorinostat combination, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03

  2. Recommended Phase 2 dose (RP2D) [ Time Frame: 16 weeks ]
    Determine the RP2D of the olaparib and vorinostat combination

  3. Antitumor activity [ Time Frame: 16 weeks ]
    Assess the antitumor activity of the olaparib and vorinostat combination in an expansion cohort of patients with relapsed/refractory and/or metastatic breast cancer, as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) 1:1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study-specific procedures.
  • Female or male ≥18 years of age.
  • Histologically or cytologically confirmed relapsed/refractory and/or metastatic breast cancer with the exception of human epidermal growth factor receptor 2-positive breast cancer.
  • Evaluable or measurable disease as per the RECIST 1:1.
  • Normal organ and bone marrow function measured within 28 days prior to administration of the study treatment.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Life expectancy ≤6 months.
  • Postmenopausal or evidence of non-childbearing status for women of childbearing potential (WOCBP): negative serum (beta-human chorionic gonadotropin) pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1.
  • WOCBP must be willing to use 2 highly effective methods of contraception for the course of the study through 1 month after the last treatment dose.
  • Male patients must be willing to use condom contraception for the course of the study through 3 months after the last treatment dose.
  • Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
  • Willing to undergo biopsy as required by the study.

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Previous allogenic bone marrow transplant or double umbilical cord blood transplantation.
  • Whole blood transfusions in the last 120 days prior to study entry.
  • Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study treatment.
  • Concomitant use of known strong or moderate cytochrome P450 (CYP)3A inhibitors.
  • Concomitant use of known strong or moderate CYP3A inducers.
  • Persistent toxicities (CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
  • Participants with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  • Known hypersensitivity to olaparib or vorinostat or any of their excipients or analogues (PARP/HDAC inhibitors).
  • Breastfeeding women.
  • No active malignancy except for non-melanoma skin cancer, in situ cervical cancer, or a treated cancer from which the patient has been continuously disease free for more than 5 years.
  • Pneumonitis or at risk of pneumonitis.
  • Uncontrolled brain or leptomeningeal metastases.
  • Any systemic chemotherapy or radiation therapy within 4 weeks prior to study entry.
  • Major surgery within 4 weeks of starting the study treatment.
  • Participation in another clinical study with an investigational product during the last 3 months.
  • Any previous treatment with PARP inhibitor including olaparib or HDAC inhibitor including vorinostat.
  • New York Heart Association Class III or IV heart failure or unstable angina.
  • History of liver disease, such as cirrhosis or active/chronic hepatitis B or C.
  • Sustained or clinically significant cardiac arrhythmias including sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block (Mobitz II or higher atrioventricular nodal block), prolonged corrected QT interval (mean >470 milliseconds), or history of acute myocardial infarction.
  • Risk factors for torsades de pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade atrioventricular nodal block.
  • Concomitant disease(s) that could prolong QT interval such as autonomic neuropathy (caused by diabetes or Parkinson's disease), human immunodeficiency virus (HIV), cirrhosis, uncontrolled hypothyroidism, or cardiac failure.
  • Concomitant medication(s) known to prolong QT interval (patient must be off the drug for 2 weeks to be eligible).
  • Presence of active or suspected acute or chronic uncontrolled infection or history of immunocompromise, including participants who are known to be serologically positive for HIV.
  • Any severe and/or uncontrolled medical conditions or other conditions that could affect study participation, such as severely impaired lung function; any active (acute or chronic) or uncontrolled infection/disorders; or non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03742245


Contacts
Layout table for location contacts
Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org
Contact: Jenny Chang, M.D. 713-441-0629 ccresearch@houstonmethodist.org

Locations
Layout table for location information
United States, Texas
Houston Methodist Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Jenny C. Chang, MD
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Jenny Chang, M.D. Houston Methodist Cancer Center

Layout table for additonal information
Responsible Party: Jenny C. Chang, MD, Director of the Houston Methodist Cancer Center, The Methodist Hospital System
ClinicalTrials.gov Identifier: NCT03742245     History of Changes
Other Study ID Numbers: Pro00020138
First Posted: November 15, 2018    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jenny C. Chang, MD, The Methodist Hospital System:
breast cancer
relapsed
refractory
metastatic

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vorinostat
Olaparib
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Poly(ADP-ribose) Polymerase Inhibitors